Immatics N.V. (NASDAQ:IMTX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Immatics N.V. (NASDAQ:IMTX) have earned an average recommendation of “Moderate Buy” from the eight analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $19.20.

Several research analysts recently weighed in on IMTX shares. Mizuho set a $25.00 price target on shares of Immatics in a research report on Thursday, February 19th. Chardan Capital reiterated a “buy” rating and set a $25.00 price objective on shares of Immatics in a research note on Monday, November 24th. Wall Street Zen cut Immatics from a “hold” rating to a “sell” rating in a report on Sunday. Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a research report on Thursday, January 22nd. Finally, Guggenheim lifted their price target on Immatics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th.

Institutional Investors Weigh In On Immatics

Hedge funds have recently modified their holdings of the business. Fox Run Management L.L.C. acquired a new position in shares of Immatics during the 2nd quarter worth approximately $136,000. Aberdeen Group plc lifted its position in Immatics by 9.7% during the third quarter. Aberdeen Group plc now owns 789,446 shares of the company’s stock worth $6,726,000 after buying an additional 69,860 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Immatics by 28.7% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 31,894 shares of the company’s stock worth $172,000 after buying an additional 7,116 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in Immatics by 8.3% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 47,635 shares of the company’s stock valued at $406,000 after buying an additional 3,666 shares in the last quarter. Finally, Monashee Investment Management LLC purchased a new stake in Immatics in the 4th quarter valued at $1,684,000. 64.41% of the stock is currently owned by institutional investors and hedge funds.

Immatics Stock Performance

NASDAQ:IMTX opened at $9.84 on Friday. The stock has a market capitalization of $1.20 billion, a PE ratio of -9.65 and a beta of 1.34. Immatics has a fifty-two week low of $3.30 and a fifty-two week high of $12.41. The company has a fifty day moving average of $9.90 and a two-hundred day moving average of $9.13.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.